Binnenkort openEuropa · Landelijk · Subsidie

Development of innovative antimicrobials against pathogens resistant to antimicrobials

Europese Commissie

Onderzoekers en farmaceutische bedrijven die willen ontwikkelen van innovatieve antimicrobiële middelen tegen resistente bacteriën en schimmels.

Ook bekend als HORIZON-HLTH-2027-01-DISEASE-08, HORIZON-HLTH-2027-01, Cluster 1 - Health (Single stage - 2027/1)

Aan de slag
Kies hoe u deze regeling aanvraagt
Gecontroleerd 10 jul 2026
Max. bedrag
€ 10 mln
per aanvraag
Eerstvolgende deadline
13 apr 2027
nog ~9 maanden

Waar is deze subsidie voor?

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to new and innovative products for the treatment of antimicrobial resistant bacteria and fungi, as well as for further clinical investigation. Candidate therapies are available to treat patients for antimicrobial resistant bacteria and fungi, increasing therapeutic options for clinical deployment in the fight against Antimicrobial Resistance (AMR). Scope: The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health. Proposals sho…

Voor wie is het bedoeld?

Onderzoekers en farmaceutische bedrijven die willen ontwikkelen van innovatieve antimicrobiële middelen tegen resistente bacteriën en schimmels.

Waarvoor kunt u subsidie krijgen?

  • Antimicrobiële resistentie bestrijding
  • Resistente bacteriën behandeling
  • Innovatieve antibiotica ontwikkeling
  • Schimmelinfecties therapie

Kom ik in aanmerking?

De eisen uit de regeling. Uw situatie bepaalt of u voldoet; dit is geen beschikking.

U bent gevestigd in de EU
Landelijke regeling.
De definitieve beoordeling ligt bij Europese Commissie.

Openstellingen en rondes

Ronde 2027Binnenkort
Start
10 feb 2027
Sluit
13 apr 2027
Budget
-
Verdeling
Tender

Bronnen en actualiteit

Dagelijks gecontroleerd
Letterlijke bron
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards…
Development of innovative antimicrobials against pathogens resistant to antimicrobials

Geen openbare bronnen beschikbaar.

Deze informatie is geautomatiseerd samengesteld uit officiële bronnen en kan onvolledig zijn. Controleer details bij de verstrekker. Elk hard feit toont een citaat uit de brontekst.